Boehringer Ingelheim GmbH and Pfizer Inc. (PFE)’s Spiriva mist inhaler for chronic lung disease may raise the risk of an early death, a review of five studies found. The use of Spiriva administered in mist form was associated with a 52 percent increase in the risk of mortality, compared with patients given only a placebo, according to the review published today in the British Medical Journal. The analysis included five clinical trials involving more than 6,500 patients.
